Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Operating Income (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Operating Income for 4 consecutive years, with $6.8 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 140.5% to $6.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$51.8 million through Dec 2025, up 19.43% year-over-year, with the annual reading at -$51.8 million for FY2025, 19.43% up from the prior year.
  • Operating Income for Q4 2025 was $6.8 million at Orchestra BioMed Holdings, up from -$20.3 million in the prior quarter.
  • The five-year high for Operating Income was $6.8 million in Q4 2025, with the low at -$20.3 million in Q3 2025.
  • Average Operating Income over 4 years is -$12.5 million, with a median of -$13.7 million recorded in 2023.
  • The sharpest move saw Operating Income crashed 125.14% in 2023, then surged 140.5% in 2025.
  • Over 4 years, Operating Income stood at -$9.8 million in 2022, then decreased by 26.99% to -$12.5 million in 2023, then tumbled by 33.62% to -$16.7 million in 2024, then soared by 140.5% to $6.8 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at $6.8 million, -$20.3 million, and -$19.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.